Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hanall Biopharma Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, showing separate examination contexts across the docket.
ABBAS, SYED JARAR is the busiest examiner, with 1 pending matter. Counsel should organize prosecution work by individual matter because no examiner or art unit is shared across the listed assignments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 25.0% | +0.0% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261368 | TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT | ABBAS, SYED JARAR | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18261409 | A STABLE OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT, WHICH IS FREE OF STABILIZER OR SUBSTANTIALLY FREE OF STABILIZER | SKELDING, ZACHARY S | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1644 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18261368 | TREATMENT OF DRY EYE SYNDROME USING AN OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT | ABBAS, SYED JARAR | 1674 | §103 | Final Rejection | 5d overdue | Pending | Jul 13, 2023 |
| 18261409 | A STABLE OPHTHALMIC COMPOSITION COMPRISING TANFANERCEPT, WHICH IS FREE OF STABILIZER OR SUBSTANTIALLY FREE OF STABILIZER | SKELDING, ZACHARY S | 1644 | §102§103DP | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18012600 | FORMULATION FOR ANTI-FCRN ANTIBODY | CHHAY, BONIRATH | 1645 | §103§112DP | Final Rejection | 53d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHanall Biopharma Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Syed Jarar Abbas has the most, with 1 of Hanall Biopharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
